BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC

- Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading IO conference SITC - Analysis comprises stage 1 (n=24) in PhII trial in 2L advanced NSCLC - Stage 2 open and enrolling BERGEN, Norway, Nov. 2, 2018 /PRNewswire/ --...

from PR Newswire: //https://ift.tt/2yMlust